HY 003 - Helperby Therapeutics
Alternative Names: HY-003 - Helperby TherapeuticsLatest Information Update: 25 Jun 2021
At a glance
- Originator Helperby Therapeutics
- Class Anti-infectives; Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Skin and soft tissue infections
Most Recent Events
- 14 Jun 2021 Preclinical trials in Skin and soft tissue infections in United Kingdom (IV), prior to June 2021 (Helperby Therapeutics pipeline, June 2021)